SingleCell’s New Assay Unlocks Cancer’s Hidden Resistance Mechanisms

DALLAS, TX – April 17, 2026 – In the complex battle against cancer, a persistent foe is not the primary tumor, but the handful of resilient cells that survive therapy and later fuel a deadly relapse. Dallas-based SingleCell Biotechnology is unveiling a powerful new lens to study these elusive cells, presenting data this week that could reshape how new cancer drugs are discovered and developed.

At the American Association for Cancer Research (AACR) Annual Meeting 2026, the company is showcasing its SCI-AP platform, a high-throughput technology designed to watch thousands of individual cancer cells simultaneously. By linking each cell's unique behavior—how it grows, moves, or enters a dormant state—to its underlying molecular makeup, the platform promises to solve one of oncology's central challenges: tumor heterogeneity. This advance offers renewed hope for treating aggressive, relapse-driven diseases, with an initial focus on the formidable brain cancer, glioblastoma.

Moving Beyond Averages to See the True Enemy

For decades, cancer research has been partially hindered by its tools. Traditional preclinical assays often measure the average response of millions of cells, effectively creating a blended, indistinct picture. While useful, this “bulk analysis” approach can completely miss the rare, stubborn cells that are the true drivers of treatment failure. It is within this cellular diversity, known as tumor heterogeneity, that the seeds of resistance are sown.

“You get a much more complete picture of what's happening,” one oncology researcher noted, speaking on the broader shift toward single-cell analysis. “Instead of looking at a smoothie of all the cells mixed together, you get to see each individual ingredient.”

SingleCell Biotechnology’s platform is engineered to analyze these “ingredients” at an unprecedented scale. The technology, presented in a poster by Machine Learning Engineer Shiska Raut, integrates microscale assays, automated imaging, and sophisticated machine learning. This allows the SCI-AP platform to track individual cells over time within their own microenvironments, capturing a full spectrum of behaviors. Crucially, it can then isolate specific cells of interest for deeper 'omics' analysis, which includes genomics, proteomics, and other molecular profiling techniques. This directly connects a cell’s actions to its biological instruction manual.

The data, presented from studies on glioblastoma models, demonstrates that the platform consistently measures subtle differences in how individual tumor cells grow and proliferate. It successfully identifies cell states, such as slow-growing or quiescent cells, that are often invisible to conventional methods but are widely believed to be responsible for cancer’s notorious ability to return.

A New Weapon in the Fight Against Glioblastoma

The company’s initial focus on glioblastoma is no accident. As one of the most aggressive and difficult-to-treat brain tumors, glioblastoma is characterized by near-universal recurrence and profound resistance to therapy. Its highly infiltrative nature makes complete surgical removal impossible, and the blood-brain barrier limits the effectiveness of many drugs.

Tumor heterogeneity is the key culprit behind this grim prognosis. A single glioblastoma tumor is a mosaic of genetically and phenotypically diverse cells, including a subpopulation of cancer stem cells that can regenerate the tumor after initial treatment. A therapy that kills 99% of cancer cells may be considered a failure if the remaining 1% are these resilient stem cells.

SingleCell Biotechnology's platform is uniquely suited to address this challenge. By providing a high-resolution map of a tumor's cellular landscape, it can help researchers identify the exact characteristics of the cells that evade treatment. The ability to test the platform on primary tumor cells taken directly from patients also opens the door for its future use as a personalized diagnostic tool, potentially guiding treatment choices based on an individual's specific tumor profile.

By understanding why certain cells survive, researchers can begin to design drugs that specifically target these resistance mechanisms, aiming not just to shrink tumors but to eradicate the cells that enable their return.

Navigating a Competitive Biotech Landscape

SingleCell Biotechnology enters a dynamic and rapidly growing market for single-cell analysis. The field is currently led by giants like 10x Genomics, whose platforms are staples in research labs for single-cell RNA sequencing, and other key players like Mission Bio and Parse Biosciences, which offer specialized multi-omic and high-throughput solutions.

However, the Dallas startup is carving out a distinct and valuable niche. While many existing platforms excel at providing a static molecular snapshot of a cell at one point in time, SingleCell’s SCI-AP platform adds a crucial dimension: function. By integrating dynamic behavioral data—growth, migration, and dormancy—with deep molecular profiling, it provides a more complete and actionable understanding of cancer biology.

This emphasis on linking phenotype to genotype at scale is the company's core differentiator. It transforms the question from “What genes does this cell have?” to “What does this specific gene expression cause the cell to do, and how can we stop it?” This approach is particularly powerful for studying cancer stem cells, the drivers of tumor recurrence that have remained a vexing target for drug developers.

A Strategically Funded Ascent

Founded in 2022, SingleCell Biotechnology is a relative newcomer, but it has made swift and strategic progress. The company’s potential was recognized early on with a significant vote of confidence from the Cancer Prevention and Research Institute of Texas (CPRIT). In 2023, SingleCell was awarded a $2.5 million product development grant to advance its platform and validate its utility in glioblastoma drug development.

This substantial, non-dilutive funding from a major state-backed cancer research agency has provided crucial runway for the company to refine its technology and generate the compelling data now being presented at AACR, one of the world's premier cancer research conferences. This backing has allowed the company to focus on its ambitious scientific goals and position itself as a serious contender in the precision oncology space.

The journey from a promising concept to a validated platform is a long one, but the data presented this week marks a significant milestone. By providing the tools to dissect tumor heterogeneity in detail, SingleCell Biotechnology’s technology has the potential to accelerate the discovery of more durable and effective cancer therapies. For patients battling relapse-driven diseases, this deeper understanding represents a new frontier of hope.